講演情報
[PL-03-1]Recent advances in clinical trials for the treatment of Parkinson disease
Olivier Rascol1,2,3 (1.Neurosciences and Clinical Pharmacology at Toulouse University Hospital, 2.Clinical Pharmacology at University of Toulouse, 3.Clinical Investigation Center INSERM)
Doctor Olivier Rascol is a neurologist specialized in Movement Disorders, Professor of Clinical Pharmacology at Toulouse University Hospital. Dr Rascol is running Toulouse Clinical Investigation Centre (CIC14136) since 1994 and Toulouse Space Clinic since 1998. He is coordinator of Toulouse Expert Center for Parkinson Disease (PD) and of the national French Reference Center for Multiple System Atrophy (MSA). Dr Rascol is the chair of the NS-Park/F-CRIN Network on clinical research in PD since 2010 and of the National French Clinical Research Infrastructure Network F-CRIN.
As a clinical neuropharmacologist, Pr Rascol’s main fields of interest are clinical trials, biomarkers and pharmaco-epidemiology of PD, MSA and other movement disorders. Pr Rascol has been involved in the development of most marketed antiparkinsonian medications within the last 30 years. He is currently running several trials for disease progression (neuroprotection) or symptomatic management of PD and MSA in collaboration with national and international academic and industry partners. Pr Rascol is a scientific advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies.
Pr Rascol has been invited worldwide to give more than 550 lectures in Europe, North America, South America and Asia, and published 600 articles in international scientific journals.
As a clinical neuropharmacologist, Pr Rascol’s main fields of interest are clinical trials, biomarkers and pharmaco-epidemiology of PD, MSA and other movement disorders. Pr Rascol has been involved in the development of most marketed antiparkinsonian medications within the last 30 years. He is currently running several trials for disease progression (neuroprotection) or symptomatic management of PD and MSA in collaboration with national and international academic and industry partners. Pr Rascol is a scientific advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies.
Pr Rascol has been invited worldwide to give more than 550 lectures in Europe, North America, South America and Asia, and published 600 articles in international scientific journals.